ARQT

NASDAQStock

Arcutis Biotherapeutics, Inc.

$22.70-0.20 (-0.89%)

52-Week Range

$12.59

$31.20

Key Stats

Market Cap

2.8B

P/E Ratio

—

Dividend Yield

—

Beta

1.74

Volume

597.4K

Avg Volume

1.6M

Performance

-14.23%

-20.86%

+35.32%

YTD

-21.00%

+56.70%

+106.21%

-29.59%

Price Chart

ETF Exposure

ARQT is held by 107 ETFs

ETF	Fund Name	Weight	Shares	Market Value	Fund AUM	Expense Ratio
ITDC	iShares LifePath Target Date 2035 ETF	0.00%	31	$735	$80.3M	0.10%
LSLT	Pacer Salt Low truBeta US Market ETF	0.00%	2,292	$59K	$6.8M	0.60%
SLT	Pacer Salt High truBeta US Market ETF	0.00%	2,292	$59K	$6.3M	0.60%
TRPL	Pacer Metaurus US Large Cap Dividend Multiplier 300 ETF	0.00%	2,292	$59K	$1.0M	0.79%
VETS	Pacer Military Times Best Employers ETF	0.00%	2,292	$59K	$1.9M	0.60%
VIRS	Pacer BioThreat Strategy ETF	0.00%	2,292	$59K	$3.7M	0.70%
VRIF.TO	Vanguard Retirement Income ETF Portfolio	0.00%	29	$1K	$337.7M	0.32%

PreviousPage 3 of 3

About ARQT ETF Exposure

Arcutis Biotherapeutics, Inc. (ARQT) is held by 107 exchange-traded funds, making it one of the stocks with significant ETF exposure. With a market capitalization of 2.8B, ARQT is a widely held institutional stock. The stock currently trades at $22.70. Investors can gain exposure to ARQT through a variety of ETFs with different expense ratios, investment strategies, and portfolio weightings. The table above shows all ETFs that currently hold ARQT, sorted by portfolio weight.